Vivo Infusion, a provider of ambulatory infusion services and a portfolio company of InTandem Capital Partners, has acquired Civic Infusion, a company focused on delivering services for infusion patients in Connecticut and New York.
Founded in 2018, Civic offers multiple therapies for acute and chronic medical conditions in areas such as allergy and immunology, gastroenterology, neurology and rheumatology. With this acquisition, Vivo Infusion will expand to 36 ambulatory infusion centers across nine states. In connection with the transaction, Civic’s co-founders Barry Stein and Robert Roteman will join Vivo Infusion as medical directors.
“We are confident that the leadership at Vivo Infusion will accelerate our growth strategy and further our goal of helping build a better future for infusion patients and referring physicians,” states Stein.